Non‑Small Cell Lung Cancer
EGFR‑positive NSCLC can be treated with tyrosine kinase inhibitors such as osimertinib, erlotinib, gefitinib, or afatinib.
Lung cancer is the leading cause of cancer deaths in men and the second most common in women, with roughly 135,000 deaths per year in the United States, surpassing deaths from prostate, breast, brain, and colorectal cancer combined.
Bizonyítékszint: Megerősített klinikai bizonyíték. Több vagy erősebb humán vizsgálat támogatja.
Kapcsolódó jelek
- Telisotuzumab Vedotin + Osimertinib for Non‑Small Cell Lung Cancer
- Ramucirumab plus erlotinib in patients with untreated, EGFR‑mutated, advanced non‑small‑cell lung cancer (RELAY): a randomised, double‑blind, placebo‑controlled, phase 3 trial
- Recent advancements in lung cancer research: a narrative review
- Advances in Non-Small Cell Lung Cancer: Current Insights and Future Directions
- Structured proxy features for multimodal NSCLC survival prediction from pretreatment CT